Further patient advocacy is needed to ensure that recipients of HCV-infected organs have access to direct-acting antivirals as early as possible, including in a prophylactic manner, if data continue to support its benefit.
The opioid epidemic has fueled the transmission of HCV, particularly among younger persons, who are often unaware of their risks and prevented from receiving timely treatment due to a variety of care barriers, even in settings ideally suited to identifying and treating HCV.
The FDA has approved updated labeling for Epclusa, Harvoni and Vosevi to include updated information regarding treatment of patients with HCV who have severe renal impairment including those with end stage renal disease who are on dialysis.
It appears that the common ancestor of the modern hepatitis E virus (HEV) strains emerged approximately 6800 years ago in the period following the domestication of pigs, and natural selection has played a major role in the evolution of the codon usage of HEV open reading frames (ORFs), according to study results published in BMC…
Front-line providers minimally could check HBV DNA and ALT during pregnancy to assess mother‐to‐child transmission risk but HBeAg is recommended to be included in the initial HBV evaluation to get a more comprehensive understanding of the patient’s HBV disease state.
Researchers of studies on the effect of conflict-driven migration on rates of hepatitis indicate that mass migration from high-burden countries has significantly increased the prevalence of both hepatitis C virus (HCV) and hepatitis B virus (HBV) infection in the host nation.
Patients with hepatitis C virus (HCV) and comorbidities, including hepatocellular carcinoma (HCC), clinically significant portal hypertension, and cirrhosis were shown to have significantly higher survival rates when treatment included directly acting antiviral agent (DAA) therapy, according to the results of several studies presented at the American Association for the Study of Liver Diseases’ The Liver…
New diagnostic tools used to identify hepatitis C virus (HCV) and hepatitis B virus (HBV) utilize simple questionnaires and emergency medical records (EMR) to alert physicians in both primary care and high-volume care settings about patients at risk for viral hepatitis infection or reactivation. The results of these studies were presented at the American Association…
Pegylated-interferon (PEG-IFN) added to nucleos(t)ide analog (NA) treatment may be associated with hepatitis B surface antigen (HbsAg) decline and once HbsAg-seroclearance is achieved, discontinuation of NA is not associated with a higher risk for HbsAg-reversion.
Data from 4 studies presented at The American Association for the Study of Liver Diseases’ The Liver Meeting 2019, held November 8 to 12 in Boston, Massachusetts, report on safety, effectiveness, and best practice approaches in patients with chronic hepatitis B, including non- and low-responders and obese patients.
Switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide fumarate (TAF) is safe and effective in patients with chronic hepatitis B (HBV) and was linked to improvements in bone, renal, and kidney function.